<DOC>
	<DOCNO>NCT02524210</DOCNO>
	<brief_summary>Dabigatran etexilate novel oral anticoagulant . It indicate venous thromboembolic prevention orthopedic surgery recently show great efficiency tolerance anticoagulant prevent thromboembolism atrial fibrillation . However , increase risk gastrointestinal bleeding compare standard treatment ( AVK ) [ 3 ] . In circumstance risk / benefit dabigatran could improve combine gastric protector inhibitor drug proton pump ( IPP ) . Investigators want evaluate pharmacokinetic pharmacodynamic effect co-administration two IPP ( omeprazole , rabeprazole ) dabigatran healthy subject .</brief_summary>
	<brief_title>Effect Inhibitors Proton Pump Intestinal Transporters</brief_title>
	<detailed_description />
	<mesh_term>Rabeprazole</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>weight 60 85 kg normal clinical exam normal biological exam hypersensitivity dabigatran excipients hypersensitivity omeprazole rabeprazole excipients previous history hemorrhagic disease insufficiency liver severe kidney failure peptic ulcer Any drug take week start study smoker Consumption grapefruit juice practice violent sport</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>volunteer</keyword>
</DOC>